How Analysts Rated CARDIOME PHARMA CORP (NASDAQ:CRME) Last Week?

May 19, 2017 - By Michael Collier

 How Analysts Rated CARDIOME PHARMA CORP (NASDAQ:CRME) Last Week?

CARDIOME PHARMA CORP (NASDAQ:CRME) Ratings Coverage

Among 5 analysts covering Cardiome Pharma Corp (NASDAQ:CRME), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Cardiome Pharma Corp had 8 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was initiated by H.C. Wainwright with “Buy” on Wednesday, June 1. The rating was downgraded by Mackie to “Hold” on Wednesday, October 12. Mackie upgraded it to “Speculative Buy” rating and $8.60 target in Friday, May 6 report. The company was downgraded on Wednesday, August 26 by Zacks. The stock of CARDIOME PHARMA CORP (NASDAQ:CRME) has “Buy” rating given on Tuesday, August 11 by Zacks. The firm has “Buy” rating given on Friday, August 14 by LB Securities. The rating was maintained by Brean Capital on Friday, March 11 with “Buy”. As per Thursday, December 22, the company rating was initiated by Leerink Swann. Below is a list of CARDIOME PHARMA CORP (NASDAQ:CRME) latest ratings and price target changes.

22/12/2016 Broker: Leerink Swann Rating: Outperform Initiate

About 353,950 shares traded or 209.11% up from the average. CARDIOME PHARMA CORP (NASDAQ:CRME) has risen 6.00% since April 19, 2017 and is uptrending. It has by 0.00% the S&P500.

Cardiome Pharma Corp. is a specialty pharmaceutical company. The company has market cap of $154.25 million. The Firm is engaged in the development and commercialization of cardiovascular therapies for heart disease. It currently has negative earnings. The Company’s divisions are Europe and Rest of World.

Investors sentiment decreased to 0.91 in 2016 Q4. Its down 1.80, from 2.71 in 2016Q3. It worsened, as 2 investors sold CARDIOME PHARMA CORP shares while 9 reduced holdings. 5 funds opened positions while 5 raised stakes. 14.48 million shares or 7.43% less from 15.64 million shares in 2016Q3 were reported.
Gp One Trading L P has 0% invested in CARDIOME PHARMA CORP (NASDAQ:CRME). Blackrock Institutional Tru Company Na owns 3,184 shares. Morgan Stanley invested in 0% or 32,703 shares. Renaissance Techs Ltd holds 0% or 215,013 shares in its portfolio. 28,900 were reported by Ardsley Advisory. Royal Savings Bank Of Canada accumulated 0% or 2,497 shares. Geode Capital Ltd holds 0% or 13,180 shares. Bancorp Of America Corp De has invested 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Jpmorgan Chase & Company accumulated 54,897 shares. Bancorp Of Montreal Can invested in 0% or 6,752 shares. Sabby Management Limited Liability Co accumulated 0.07% or 437,720 shares. Pnc Fin Services Group stated it has 0% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Putnam Invests Lc has invested 0.02% of its portfolio in CARDIOME PHARMA CORP (NASDAQ:CRME). Credit Suisse Ag has invested 0% in CARDIOME PHARMA CORP (NASDAQ:CRME). Clough Cap Ptnrs Lp owns 3.06M shares.

More important recent CARDIOME PHARMA CORP (NASDAQ:CRME) news were published by: Zacks.com which released: “Cardiome Pharma (CRME) Looks Good: Stock Moves 6.1% Higher” on May 18, 2017, also Streetinsider.com published article titled: “Cardiome Pharma (CRME) Names Justin Renz as CFO; Jennifer Archibald Appointed …”, Stockhouse.com published: “Investor Network: Cardiome Pharma Corp. to Host Earnings Call” on May 15, 2017. More interesting news about CARDIOME PHARMA CORP (NASDAQ:CRME) was released by: Seekingalpha.com and their article: “Cardiome Pharma’s (CRME) CEO Bill Hunter on Q4 2016 Results – Earnings Call …” with publication date: March 08, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.